Aurobindo Pharma Limited
AUROPHARMA
Kedudukan dalam Saham
#2074
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures,... Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Harga Saham
$17.34
Modal Pasaran
$9.98B
Perubahan (1 hari)
-3.08%
Perubahan (1 tahun)
38.71%
Negara
IN
Perdagangan Aurobindo Pharma Limited (AUROPHARMA)
Kategori
Healthcare
Pendapatan untuk Aurobindo Pharma Limited (AUROPHARMA)
Pendapatan pada Jun 2026 TTM: $598.16M
Menurut laporan kewangan terkini Aurobindo Pharma Limited, pendapatan semasa syarikat ialah $598.16M. Pada tahun 2024, syarikat memperoleh pendapatan sebanyak $525.28M, peningkatan berbanding pendapatan pada tahun 2023 yang berjumlah $317.90M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Aurobindo Pharma Limited dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $598.16M | 0.98% |
| 2025 | $592.37M | 12.77% |
| 2024 | $525.28M | 65.24% |
| 2023 | $317.90M | -28.45% |
| 2022 | $444.31M | -55.71% |
| 2021 | $1.00B | 101.91% |
| 2020 | $496.85M | 11.61% |
| 2019 | $445.18M | -10.57% |
| 2018 | $497.80M | 5.47% |
| 2017 | $471.99M | 13.94% |
| 2016 | $414.23M | 19.23% |
| 2015 | $347.42M | -3.94% |
| 2014 | $361.67M | 425.28% |
| 2013 | $68.85M | -263.95% |
| 2012 | $-42.00M | -123.75% |
| 2011 | $176.86M | 5.59% |
| 2010 | $167.49M | 1,070.92% |
| 2009 | $14.30M | -80.38% |
| 2008 | $72.91M | 53.10% |
| 2007 | $47.62M | 115.32% |
| 2006 | $22.12M | 427.99% |
| 2005 | $4.19M | -88.08% |
| 2004 | $35.14M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 195.00% |
IN
|
